[go: up one dir, main page]

RU2016143384A - Трансгенные генетические метки и способы применения - Google Patents

Трансгенные генетические метки и способы применения Download PDF

Info

Publication number
RU2016143384A
RU2016143384A RU2016143384A RU2016143384A RU2016143384A RU 2016143384 A RU2016143384 A RU 2016143384A RU 2016143384 A RU2016143384 A RU 2016143384A RU 2016143384 A RU2016143384 A RU 2016143384A RU 2016143384 A RU2016143384 A RU 2016143384A
Authority
RU
Russia
Prior art keywords
paragraphs
polypeptide
host cell
seq
antibody
Prior art date
Application number
RU2016143384A
Other languages
English (en)
Other versions
RU2016143384A3 (ru
RU2729112C2 (ru
Inventor
Майкл К. ДЖЕНСЕН
Адам ДЖОНСОН
Original Assignee
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016143384(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) filed Critical Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют)
Publication of RU2016143384A publication Critical patent/RU2016143384A/ru
Publication of RU2016143384A3 publication Critical patent/RU2016143384A3/ru
Application granted granted Critical
Publication of RU2729112C2 publication Critical patent/RU2729112C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)

Claims (53)

1. Выделенный полипептид, который по меньшей мере на 95% идентичен последовательности полипептида внеклеточного домена полипептида Her2, содержащего последовательность аминокислот с 563 по 652 последовательности, представленной в SEQ ID NO: 23, соединенного с трансмембранным доменом, причем указанный выделенный полипептид специфично связывается с антителом, которое связывается с эпитопом в домене IV Her2, и при этом указанный выделенный полипептид не включает полноразмерный зрелый Her2.
2. Выделенный полипептид по п. 1, отличающийся тем, что указанный полипептид Her2 содержит такие аминокислоты как глутаминовая кислота в положении 580, аспарагиновая кислота в положении 582, аспарагиновая кислота в положении 592, фенилаланин в положении 595 и глутамин в положении 624 последовательности, представленной в SEQ ID NO: 23.
3. Выделенный полипептид по п. 2, отличающийся тем, что указанный полипептид Her2 содержит аминокислоты 563-652 последовательности, представленной в SEQ ID NO: 23.
4. Выделенный полипептид по любому из пп. 1-3, отличающийся тем, что указанный трансмембранный домен содержит аминокислоты 653-675 последовательности, представленной в SEQ ID NO: 23.
5. Выделенный полипептид по любому из пп. 1-3, дополнительно содержащий лидерный пептид, который обеспечивает экспрессию на поверхности клеток.
6. Выделенный полипептид по п. 5, отличающийся тем, что указанный лидерный пептид содержит аминокислотную последовательность, представленную в SEQ ID NO: 17.
7. Выделенный полипептид по любому из пп. 1-3, 6, отличающийся тем, что указанное антитело представляет собой трастузумаб.
8. Выделенный полипептид, который по меньшей мере на 95% идентичен последовательности полипептида внеклеточного домена полипептида Her2, содержащего последовательность аминокислот с 563 по 652 последовательности, представленной в SEQ ID NO: 23, соединенного с трансмембранным доменом, причем указанный выделенный полипептид специфично связывается с антителом, которое связывается с эпитопом в домене IV Her2, и при этом указанный выделенный полипептид не включает полноразмерный зрелый Her, и при этом внеклеточный домен полипептида Her2, содержащий последовательность аминокислот с 563 по 652 последовательности, представленной в SEQ ID NO: 23, соединен с трансмембранным доменом последовательностью, содержащей аминокислоты GGGSGGGS (SEQ ID NO: 45).
9. Выделенный полипептид по п. 8, отличающийся тем, что указанный полипептид Her2 содержит такие аминокислоты как глутаминовая кислота в положении 580, аспарагиновая кислота в положении 582, аспарагиновая кислота в положении 592, фенилаланин в положении 595 и глутамин в положении 624 последовательности, представленной в SEQ ID NO: 23.
10. Выделенный полипептид по п. 9, отличающийся тем, что указанный полипептид Her2 содержит аминокислоты 563-652 последовательности, представленной в SEQ ID NO: 23.
11. Выделенный полипептид по любому из пп. 8-10, отличающийся тем, что указанный трансмембранный домен содержит аминокислоты 653-675 последовательности, представленной в SEQ ID NO: 23.
12. Выделенный полипептид по любому из пп. 8-10, дополнительно содержащий лидерный пептид, который обеспечивает экспрессию на поверхности клеток.
13. Выделенный полипептид по п. 12, отличающийся тем, что указанный лидерный пептид содержит аминокислотную последовательность, представленную в SEQ ID NO: 17.
14. Выделенный полипептид по любому из пп. 8-10, 13, отличающийся тем, что указанное антитело представляет собой трастузумаб.
15. Выделенная нуклеиновая кислота, кодирующая полипептид по любому из пп. 1-14.
16. Выделенная нуклеиновая кислота по п. 15, дополнительно содержащая промотор.
17. Выделенная нуклеиновая кислота по п. 15 или 16, дополнительно содержащая трансген.
18. Выделенная нуклеиновая кислота по п. 17, отличающаяся тем, что указанный трансген содержит полинуклеотид, кодирующий химерный антигенный рецептор.
19. Выделенная нуклеиновая кислота по п. 18, отличающаяся тем, что указанный химерный антигенный рецептор содержит антигенсвязывающий домен, спейсерный участок, трансмембранный домен и по меньшей мере один стимулирующий домен.
20. Выделенная нуклеиновая кислота по любому из пп. 18-19, отличающаяся тем, что указанный полинуклеотид, кодирующий трансген, соединен с нуклеиновой кислотой, кодирующей полипептид Her2 по п. 1, с помощью саморасщепляющегося линкера.
21. Выделенная нуклеиновая кислота по п. 20, отличающаяся тем, что указанный саморасщепляющийся линкер представляет собой линкер Т2А, содержащий последовательность LEGGGEGRGSLLTCG (SEQ ID NO: 26).
22. Выделенная нуклеиновая кислота по любому из пп. 18-19, 21 отличающаяся тем, что указанный химерный антигенный рецептор содержит аминокислотную последовательность, представленную в SEQ ID NO: 2.
23. Выделенная нуклеиновая кислота по любому из пп. 18-19, 21 отличающаяся тем, что указанный химерный антигенный рецептор содержит аминокислотную последовательность, представленную в SEQ ID NO: 25 (CD20CAR).
24. Клетка-хозяин, содержащая выделенную нуклеиновую кислоту по любому из пп. 15-23.
25. Клетка-хозяин по п. 24, отличающаяся тем, что указанная клетка-хозяин выбрана из группы, состоящей из CD8 Т-клеток, CD4 Т-клеток, CD4 наивных Т-клеток, CD8 наивных Т-клеток, CD8 клеток центральной памяти, CD4 клеток центральной памяти и их комбинаций.
26. Клетка-хозяин по п. 24 или 25, отличающаяся тем, что указанная клетка-хозяин является аутологичной.
27. Клетка-хозяин по любому из пп. 24-25, отличающаяся тем, что указанная клетка-хозяин является антигенспецифичной.
28. Клетка-хозяин по п. 24, отличающаяся тем, что указанная клетка-хозяин представляет собой клетку-предшественника Т-лимфоцитов.
29. Клетка-хозяин по п. 24, отличающаяся тем, что указанная клетка-хозяин представляет собой гемопоэтическую стволовую клетку.
30. Клетка-хозяин по любому из пп. 24-25, отличающаяся тем, что указанная клетка-хозяин представляет собой клетку-предшественника Т-лимфоцитов.
31. Клетка-хозяин по любому из пп. 24-25, отличающаяся тем, что указанная клетка-хозяин представляет собой гемопоэтическую стволовую клетку.
32. Композиция, содержащая клетку-хозяина по любому из пп. 24-31.
33. Способ изготовления композиции, включающий:
a) введение выделенной нуклеиновой кислоты по любому из пп. 15-23 в клетку-хозяина; и
b) культивирование указанных клеток-хозяев в среде, содержащей по меньшей мере один фактор роста.
34. Способ по п. 33, отличающийся тем, что указанный фактор роста выбран из группы, состоящей из ИЛ-15, ИЛ-7, ИЛ-21, ИЛ-2 и их комбинаций.
35. Способ по п. 33 или 34, дополнительно включающий отбор клеток, которые экспрессируют полипептид Her2t.
36. Способ по любому из пп. 33-34, отличающийся тем, что указанные клетки отбирают перед культивированием клеток в среде.
37. Способ по любому из пп. 33-34, отличающийся тем, что указанные клетки отбирают с применением антитела, которое связывается с доменом IV Her2.
38. Способ по п. 37, отличающийся тем, что указанное антитело представляет собой трастузумаб.
39. Способ по любому из пп. 33-34, 38, дополнительно включающий введение второй выделенной нуклеиновой кислоты, кодирующей химерный антигенный рецептор, соединенный со второй генетической меткой.
40. Способ по п. 39, дополнительно включающий отбор клеток, экспрессирующих вторую генетическую метку.
41. Способ по п. 39, отличающийся тем, что указанная вторая генетическая метка содержит EGFRt.
42. Способ лечения пациента, страдающего раком, экспрессирующим опухолевый антиген, включающий введение эффективного количества композиции по п. 32, причем клетки указанной композиции экспрессируют химерный антигенный рецептор, который содержит антигенсвязывающий домен, связывающийся с опухолевым антигеном, экспрессируемым на раковой клетке, и генетическую метку.
43. Способ лечения пациента, страдающего раком, экспрессирующим опухолевый антиген, включающий введение эффективного количества композиции по п. 32 и антитела, которое специфично связывается с генетической меткой, при этом клетки указанной композиции экспрессируют химерный антигенный рецептор, который содержит антигенсвязывающий домен, связывающийся с опухолевым антигеном, экспрессируемым на раковой клетке, и генетическую метку.
44. Способ по любому из пп. 42-43, отличающееся тем, что указанное антитело представляет собой герцептин или эрбитукс.
45. Способ по любому из пп. 42-43, отличающееся тем, что указанное антитело конъюгировано с цитотоксическим агентом.
46. Способ по любому из пп. 42-43, отличающееся тем, что указанное антитело содержит детектируемую метку.
47. Применение композиции по п. 32 для лечения рака, содержащего опухолевый антиген, который распознается химерным антигенным рецептором на поверхности клеток.
48. Применение композиции по п. 32 для лечения рака, содержащего опухолевый антиген, который распознается химерным антигенным рецептором на клетках композиции, и антитела, которое специфично связывается с генетической меткой.
49. Применение по любому из пп. 47-48, отличающееся тем, что указанное антитело представляет собой герцептин или эрбитукс.
50. Применение по любому из пп. 47-48, отличающееся тем, что указанное антитело конъюгировано с цитотоксическим агентом.
51. Применение по любому из пп. 47-48, отличающееся тем, что указанное антитело содержит детектируемую метку.
RU2016143384A 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения RU2729112C2 (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201461977751P 2014-04-10 2014-04-10
US61/977,751 2014-04-10
US201461986479P 2014-04-30 2014-04-30
US61/986,479 2014-04-30
US201462058973P 2014-10-02 2014-10-02
US62/058,973 2014-10-02
US201462088363P 2014-12-05 2014-12-05
US62/088,363 2014-12-05
US201462089730P 2014-12-09 2014-12-09
US62/089,730 2014-12-09
US201462090845P 2014-12-11 2014-12-11
US62/090,845 2014-12-11
PCT/US2015/024895 WO2015157399A1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020124619A Division RU2822461C1 (ru) 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения

Publications (3)

Publication Number Publication Date
RU2016143384A true RU2016143384A (ru) 2018-05-11
RU2016143384A3 RU2016143384A3 (ru) 2018-11-30
RU2729112C2 RU2729112C2 (ru) 2020-08-04

Family

ID=54288361

Family Applications (5)

Application Number Title Priority Date Filing Date
RU2016143385A RU2751921C2 (ru) 2014-04-10 2015-04-08 Продукты определенного состава, содержащие генетически модифицированные т-клетки
RU2016143384A RU2729112C2 (ru) 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения
RU2016143389A RU2016143389A (ru) 2014-04-10 2015-04-08 Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
RU2016143381A RU2752275C2 (ru) 2014-04-10 2015-04-08 Способ и композиции для клеточной иммунотерапии
RU2016143388A RU2751920C2 (ru) 2014-04-10 2015-04-08 Экспрессия трансгенов, регулируемая лекарственным средством

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016143385A RU2751921C2 (ru) 2014-04-10 2015-04-08 Продукты определенного состава, содержащие генетически модифицированные т-клетки

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU2016143389A RU2016143389A (ru) 2014-04-10 2015-04-08 Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
RU2016143381A RU2752275C2 (ru) 2014-04-10 2015-04-08 Способ и композиции для клеточной иммунотерапии
RU2016143388A RU2751920C2 (ru) 2014-04-10 2015-04-08 Экспрессия трансгенов, регулируемая лекарственным средством

Country Status (19)

Country Link
US (12) US10266592B2 (ru)
EP (8) EP3954708A1 (ru)
JP (12) JP6765967B2 (ru)
KR (8) KR102508166B1 (ru)
CN (7) CN113528581A (ru)
AU (8) AU2015243922B2 (ru)
BR (3) BR112016023517A2 (ru)
CA (4) CA2945308C (ru)
ES (2) ES2880932T3 (ru)
IL (5) IL248243B2 (ru)
MX (6) MX2016013158A (ru)
MY (4) MY186846A (ru)
NZ (3) NZ725079A (ru)
PH (4) PH12016502010B1 (ru)
RU (5) RU2751921C2 (ru)
SA (1) SA516380056B1 (ru)
SG (8) SG11201608395PA (ru)
WO (5) WO2015157432A1 (ru)
ZA (3) ZA201607053B (ru)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548667C (zh) * 2003-01-20 2009-10-14 日本瑞翁株式会社 层合件及其制造方法
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2015075470A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell
PH12016502010B1 (en) * 2014-04-10 2023-08-16 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
CN113046321A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
US10494422B2 (en) 2014-04-29 2019-12-03 Seattle Children's Hospital CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
CA2964941A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
ES2983094T3 (es) 2014-10-31 2024-10-21 Univ Pennsylvania Alteración de la expresión génica en células CAR-T y usos de los mismos
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
SG10201901707QA (en) 2014-12-05 2019-03-28 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
CA2973964A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CA2976126A1 (en) * 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
CN107249602B (zh) 2015-02-27 2021-09-28 美商生物细胞基因治疗有限公司 靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法
IL254817B2 (en) * 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
CN107849112B (zh) 2015-06-25 2022-04-01 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
CA2994829A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
CN108601849A (zh) 2015-09-22 2018-09-28 尤利乌斯·马克西米利安维尔茨堡大学 一种在淋巴细胞中高水平的和稳定的基因转移的方法
IL299114A (en) * 2015-10-06 2023-02-01 Hope City Chimeric antigen receptors targeting PSCA
CA3001710A1 (en) * 2015-10-23 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Prognosis and treatment of squamous cell carcinomas
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
WO2017079703A1 (en) * 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
CN116334143A (zh) * 2015-11-23 2023-06-27 诺华股份有限公司 优化的慢病毒转移载体及其用途
NZ742068A (en) * 2015-12-14 2023-07-28 Genomefrontier Therapeutics Inc Transposon system, kit comprising the same, and uses thereof
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3430549A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
AU2017276706B2 (en) * 2016-06-07 2024-08-15 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
IL321834A (en) * 2016-06-08 2025-08-01 Precigen Inc Cd33 specific chimeric antigen receptors
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018075941A1 (en) * 2016-10-21 2018-04-26 Washington University Ap4 and methods of promoting t cell activation
JP2019536786A (ja) * 2016-11-30 2019-12-19 イントレキソン コーポレーション ステロイドの投与および免疫療法
MX2019006288A (es) 2016-12-03 2020-10-01 Juno Therapeutics Inc Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa.
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN106800601B (zh) * 2017-01-19 2021-04-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
MX2019008538A (es) * 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
EP4353818A3 (en) 2017-02-27 2024-06-19 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
KR102771581B1 (ko) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
CN106963945A (zh) * 2017-03-27 2017-07-21 山东兴瑞生物科技有限公司 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
CA3063695A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
KR102460173B1 (ko) * 2017-05-26 2022-10-31 주식회사 지씨셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN107335054B (zh) * 2017-06-30 2021-01-15 山东兴瑞生物科技有限公司 一种慢性乙肝治疗性dc疫苗
KR102486090B1 (ko) 2017-08-07 2023-01-10 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
JP2020535114A (ja) * 2017-08-11 2020-12-03 トリビオティカ・エルエルシー テンプレート化アセンブリによって認識分子に結合するエピトープの生成方法
KR102804751B1 (ko) * 2017-08-23 2025-05-13 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
MX2020007357A (es) * 2017-09-26 2021-08-11 Longwood Univ Reporte de antígeno quimérico específico de pd1 como una inmunoterapia.
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
KR102742741B1 (ko) 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
EP3704230B1 (en) * 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
WO2019094482A1 (en) 2017-11-10 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting tumor antigens
CA3082570A1 (en) * 2017-11-14 2019-05-23 Memorial Sloan-Kettering Cancer Center Il-36 secreting immunoresponsive cells and uses thereof
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN108383914A (zh) 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
WO2019178613A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2019222112A1 (en) 2018-05-14 2019-11-21 Gilead Sciences, Inc. Mcl-1 inhibitors
CA3100446A1 (en) * 2018-05-15 2019-11-21 Carsgen Therapeutics Co., Ltd. Genetically engineered cell and application thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
US12497611B2 (en) 2018-08-17 2025-12-16 Yale University Compositions and methods for high-throughput activation screening to boost T cell effector function
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
WO2020044239A1 (en) * 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US12173071B2 (en) 2018-08-31 2024-12-24 Seattle Children's Hospital Methods and compositions comprising B7H3 chimeric antigen receptors
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CA3116294C (en) * 2018-10-19 2023-10-24 Cartexell Inc. Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
ES3035857T3 (en) 2018-11-01 2025-09-10 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CA3120085A1 (en) 2018-11-14 2020-05-22 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed t-cells
AU2019381827A1 (en) * 2018-11-16 2021-06-10 Juno Therapeutics, Inc. Methods of dosing engineered T cells for the treatment of B cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
EP3886894B1 (en) * 2018-11-30 2024-03-13 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
MX2021006402A (es) * 2018-11-30 2021-08-11 Celularity Inc Celulas t-car alogenicas derivadas de placenta y usos de las mismas.
WO2020113194A2 (en) * 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2019401282A1 (en) * 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020191172A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
US20220195414A1 (en) * 2019-04-08 2022-06-23 Russell Biotech, Inc. Improved Manufacturing Procedures for Cell Based Therapies
CN109994176A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含样本类型信息管理模块的精准用药智能报告系统
CN109994180A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含基因位点信息管理模块的精准用药智能报告系统
CN109994156A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含报告模板信息管理模块的精准用药智能报告系统
CN110010222A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基于精准用药知识库的基因身份识别系统
CN109979545A (zh) * 2019-04-16 2019-07-05 北京中佰耀因医药科技有限公司 一种含样本状态信息管理模块的精准用药智能报告系统
CN110010200A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基因身份识别系统
CN109872792A (zh) * 2019-04-16 2019-06-11 北京中佰耀因医药科技有限公司 一种用于指导精准用药的基因检测智能报告系统
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020286471B2 (en) * 2019-06-07 2025-07-31 The Trustees Of The University Of Pennsylvania Dual CAR expressing T cells individually linked to CD28 and 4-1BB
US20210030795A1 (en) * 2019-06-17 2021-02-04 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
CN114222763A (zh) * 2019-06-19 2022-03-22 尤利乌斯·马克西米利安维尔茨堡大学 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN110608991B (zh) * 2019-09-09 2022-04-29 浙江普罗亭健康科技有限公司 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
HRP20241518T1 (hr) 2019-12-24 2025-01-03 Carna Biosciences, Inc. Spojevi koji moduliraju diacilglicerinkinazu
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
JP2023518293A (ja) 2020-03-20 2023-04-28 ライル・イミュノファーマ，インコーポレイテッド 新規の組換え細胞表面マーカー
US12110294B2 (en) 2020-05-01 2024-10-08 Gilead Sciences, Inc. CD73 compounds
GB202007169D0 (en) * 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN115803038A (zh) * 2020-06-08 2023-03-14 西雅图儿童医院（Dba西雅图儿童研究所） 抗cd171嵌合抗原受体
WO2022007938A1 (en) * 2020-07-09 2022-01-13 Nanjing Legend Biotech Co., Ltd. Engineering gamma delta t cells with interleukin-36 for immunotherapy
CA3188656A1 (en) 2020-07-17 2022-01-20 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
AU2021397206A1 (en) * 2020-12-08 2023-07-27 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4277639A4 (en) * 2021-01-15 2025-03-05 Seattle Children's Hospital d/b/a Seattle Children's Research Institute HYBRID AND TRUNCATED IMMUNE CELL PROTEINS
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4394043A4 (en) * 2021-08-24 2025-09-03 Cells & Genes Biotech Shanghai Co Ltd CELL MODIFICATION METHOD
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023173137A1 (en) * 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
JP2025509610A (ja) 2022-03-17 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4504243A1 (en) * 2022-04-01 2025-02-12 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
JP2025513258A (ja) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａ ｇ１２ｄ調節化合物
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
WO2023227900A1 (en) * 2022-05-27 2023-11-30 Autolus Limited Method
UY40304A (es) * 2022-06-10 2023-12-29 Biocad Joint Stock Co Ácido nucleico con actividad promotora y uso del mismo
WO2024006702A1 (en) * 2022-06-27 2024-01-04 Foundation Medicine, Inc. Methods and systems for predicting genotypic calls from whole-slide images
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
CN120435300A (zh) * 2022-12-15 2025-08-05 莱兰斯坦福初级大学评议会 人t细胞中的非同源依赖性靶向dna插入
EP4638486A2 (en) * 2022-12-20 2025-10-29 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
JP2026502616A (ja) * 2023-01-19 2026-01-23 ウーハン チャオチー バイオテクノロジー カンパニー リミテッド Ｃａｒ分子、それを含む細胞若しくはエクソソーム、及びそれらの使用
US20240290628A1 (en) * 2023-02-24 2024-08-29 American Air Liquide, Inc. Etching method using oxygen-containing hydrofluorocarbon
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
CN116844685B (zh) * 2023-07-03 2024-04-12 广州默锐医药科技有限公司 一种免疫治疗效果评估方法、装置、电子设备及存储介质
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US20020111474A1 (en) * 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
WO1994000143A1 (en) 1992-06-01 1994-01-06 New England Medical Center Hospitals, Inc. Blocking intercellular interactions with cd43 chimeric molecules
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6410319B1 (en) * 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040037816A1 (en) 1999-04-15 2004-02-26 Monash University Graft acceptance through manipulation of thymic regeneration
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
JP4045713B2 (ja) 2000-01-31 2008-02-13 松下電器産業株式会社 自動機用溶接機
GB0015119D0 (en) * 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) * 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
EP1397382B1 (en) 2001-05-31 2008-08-06 Novartis AG Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
IL160933A0 (en) 2001-09-18 2004-08-31 Proteologics Inc Methods and compositions for treating ?cap associated diseases
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
EP1572939A4 (en) 2002-04-11 2006-08-30 Amgen Inc HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
CA2516455C (en) * 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004092338A2 (en) 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1809277A (zh) * 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的移植物耐受
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
JP4772674B2 (ja) 2003-07-21 2011-09-14 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途
JP2007535906A (ja) * 2003-10-24 2007-12-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 直交遺伝子スイッチ
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
DE202005002921U1 (de) 2005-02-23 2005-04-21 Magcode Ag Verbindungssystem, insbesondere elektrisches Verbindungssystem
JP2008541764A (ja) 2005-06-01 2008-11-27 バイオテック・インスティチュート・フォー・インターナショナル・イノベーション・インコーポレーテッド グルコース誘導性のインシュリンの発現及び糖尿病を治療する方法
RU2008129827A (ru) 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
JP2009538144A (ja) 2006-05-22 2009-11-05 ハイプロセル・リミテッド・ライアビリティ・カンパニー 真核細胞株を用いたタンパク質産生
US8148129B2 (en) 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) * 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
EP2587263A1 (en) * 2007-07-25 2013-05-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Self coupling recombinant antibody fusion proteins
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EP2279253B1 (en) * 2008-04-09 2016-11-16 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
JP5684130B2 (ja) * 2008-09-26 2015-03-11 トカジェン インコーポレーテッド 組換えベクター
US8329882B2 (en) * 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
EP2438443A4 (en) 2009-06-02 2012-07-25 Targeted Molecular Diagnostics Llc METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2)
US9873035B2 (en) * 2009-07-09 2018-01-23 Cfph, Llc Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CA2776143A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011056894A2 (en) 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
ES2602743T3 (es) * 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US9476028B2 (en) 2011-04-13 2016-10-25 Immunicum Ab Method for proliferation of antigen-specific T cells
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
PL2723773T3 (pl) * 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
IN2014CN02906A (ru) 2011-10-20 2015-07-03 Us Health
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
ITRM20120058A1 (it) * 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
EP4230647A1 (en) * 2012-02-22 2023-08-23 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
KR20210032014A (ko) * 2012-04-11 2021-03-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US20140056868A1 (en) 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
US9792559B2 (en) 2012-06-01 2017-10-17 Nec Corporation Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program
ES2842102T3 (es) 2012-08-20 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
NZ746914A (en) 2012-10-02 2020-03-27 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
WO2014099671A1 (en) * 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
CA2904369A1 (en) * 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
RU2733652C2 (ru) 2013-10-31 2020-10-06 Фред Хатчинсон Кэнсер Рисерч Сентер МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ
WO2015075470A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
EP3082847A1 (en) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
CN105873948B (zh) 2014-01-15 2021-04-13 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
PH12016502010B1 (en) * 2014-04-10 2023-08-16 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
DE112014006656B4 (de) 2014-05-14 2018-05-17 Carsgen Therapeutics Limited Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins
SG11201609960QA (en) 2014-06-02 2016-12-29 Us Health Chimeric antigen receptors targeting cd-19
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
CN107106611B (zh) 2014-10-27 2021-11-23 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
SG10201914069SA (en) 2015-05-18 2020-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
AU2016277121C1 (en) 2015-06-12 2022-07-14 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
WO2017136829A1 (en) 2016-02-05 2017-08-10 City Of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
CN109415409B (zh) 2016-04-01 2022-03-15 亘喜生物科技（上海）有限公司 Flag标记的cd19-car-t细胞
TWI719894B (zh) 2016-09-28 2021-02-21 美商凱特製藥公司 抗原結合分子類和使用彼等之方法
EP3523326B1 (en) 2016-10-04 2020-06-03 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EP3749695A4 (en) 2018-02-06 2021-12-29 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210317407A1 (en) 2018-08-06 2021-10-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
US10714296B2 (en) 2018-12-12 2020-07-14 Axcelis Technologies, Inc. Ion source with tailored extraction shape
US11104732B2 (en) 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15

Also Published As

Publication number Publication date
KR20220153100A (ko) 2022-11-17
CN112877291A (zh) 2021-06-01
JP7508516B2 (ja) 2024-07-01
AU2015243922B2 (en) 2021-08-05
IL248229B1 (en) 2023-01-01
EP3129471A1 (en) 2017-02-15
PH12016502009A1 (en) 2017-01-09
US10865242B2 (en) 2020-12-15
BR112016023523A2 (pt) 2017-10-17
AU2015243849B2 (en) 2020-12-17
CA2945305A1 (en) 2015-10-15
JP7093385B2 (ja) 2022-06-29
IL248243B1 (en) 2023-12-01
AU2015243927B2 (en) 2021-09-02
IL248243B2 (en) 2024-04-01
MX2016013158A (es) 2017-04-27
JP7542270B2 (ja) 2024-08-30
PH12016502011B1 (en) 2022-06-17
KR20160144431A (ko) 2016-12-16
CA2945302A1 (en) 2015-10-15
MX389797B (es) 2025-03-20
AU2015243849A1 (en) 2016-11-03
AU2015243882A1 (en) 2016-11-03
EP3129471A4 (en) 2017-11-08
KR102618955B9 (ko) 2024-08-12
EP3129053A4 (en) 2017-11-08
AU2021201679B2 (en) 2023-05-04
EP3954708A1 (en) 2022-02-16
SA516380056B1 (ar) 2021-07-04
SG11201608393TA (en) 2016-11-29
JP2017513470A (ja) 2017-06-01
JP2017515464A (ja) 2017-06-15
WO2015157391A1 (en) 2015-10-15
KR102600544B1 (ko) 2023-11-09
US20170029774A1 (en) 2017-02-02
CN106573969A (zh) 2017-04-19
US12448445B2 (en) 2025-10-21
JP2017513520A (ja) 2017-06-01
SG10201808819XA (en) 2018-11-29
KR20160144432A (ko) 2016-12-16
EP3129399B1 (en) 2021-05-26
EP3129405A4 (en) 2017-08-09
IL248235B (en) 2021-01-31
BR112016023507A2 (pt) 2017-10-17
KR20220051024A (ko) 2022-04-25
WO2015157384A1 (en) 2015-10-15
JP7106610B2 (ja) 2022-07-26
JP2022109953A (ja) 2022-07-28
US20220064292A1 (en) 2022-03-03
US20180009891A1 (en) 2018-01-11
AU2021273652A1 (en) 2021-12-16
JP2017512484A (ja) 2017-05-25
KR20160144430A (ko) 2016-12-16
CA2945308C (en) 2023-10-31
US12258397B2 (en) 2025-03-25
EP3129480A1 (en) 2017-02-15
AU2015243922A1 (en) 2016-11-03
BR112016023513A2 (pt) 2017-10-17
JP6765968B2 (ja) 2020-10-07
RU2016143385A (ru) 2018-05-15
MX2022010807A (es) 2022-09-27
NZ758289A (en) 2024-01-26
CN106536558A (zh) 2017-03-22
IL248243A0 (en) 2016-11-30
KR102463529B9 (ko) 2024-07-31
US20210139583A1 (en) 2021-05-13
KR102463529B1 (ko) 2022-11-07
KR20160143762A (ko) 2016-12-14
RU2016143381A3 (ru) 2018-11-30
IL248238B2 (en) 2025-02-01
IL248229B2 (en) 2023-05-01
CA2945308A1 (en) 2015-10-15
US20190248891A1 (en) 2019-08-15
JP2021019589A (ja) 2021-02-18
EP3129399A4 (en) 2017-11-08
SG10201808833XA (en) 2018-11-29
AU2021200007B2 (en) 2024-08-29
AU2021201679A1 (en) 2021-04-08
WO2015157386A1 (en) 2015-10-15
MX2016013159A (es) 2017-04-27
RU2016143381A (ru) 2018-05-11
ZA201607060B (en) 2024-05-30
CA2945305C (en) 2023-10-17
IL297591A (en) 2022-12-01
PH12016502010A1 (en) 2017-01-09
KR20230038310A (ko) 2023-03-17
MX2016013144A (es) 2017-04-27
ZA201607053B (en) 2025-03-26
AU2015243927A1 (en) 2016-11-03
KR102730216B1 (ko) 2024-11-14
JP7402933B2 (ja) 2023-12-21
SG10201808811QA (en) 2018-11-29
JP2021036867A (ja) 2021-03-11
EP3129405A1 (en) 2017-02-15
JP6765967B2 (ja) 2020-10-14
SG11201608392WA (en) 2016-11-29
CN106661570A (zh) 2017-05-10
AU2015243920B2 (en) 2020-10-08
RU2016143389A (ru) 2018-05-15
PH12016502010B1 (en) 2023-08-16
EP3129399A1 (en) 2017-02-15
SG10201808825XA (en) 2018-11-29
RU2016143385A3 (ru) 2018-11-30
CN106573969B (zh) 2021-07-30
EP3129405B1 (en) 2021-02-24
WO2015157399A1 (en) 2015-10-15
US20170015746A1 (en) 2017-01-19
US20220372140A1 (en) 2022-11-24
AU2015243882C1 (en) 2024-07-25
US11155616B2 (en) 2021-10-26
EP3129480A4 (en) 2017-08-16
JP7148580B2 (ja) 2022-10-05
IL248229A (en) 2016-11-30
WO2015157432A1 (en) 2015-10-15
IL297591B2 (en) 2025-05-01
NZ725079A (en) 2018-03-23
US12202897B2 (en) 2025-01-21
US11414486B2 (en) 2022-08-16
JP2017518037A (ja) 2017-07-06
MX387465B (es) 2025-03-18
BR112016023500B1 (pt) 2024-04-30
AU2015243849A9 (en) 2019-07-25
MY184163A (en) 2021-03-24
RU2751921C2 (ru) 2021-07-20
AU2015243882B2 (en) 2020-03-12
MX2016013149A (es) 2017-04-27
US10611837B2 (en) 2020-04-07
JP2020195380A (ja) 2020-12-10
RU2016143389A3 (ru) 2018-12-04
JP2022184989A (ja) 2022-12-13
ES2867224T3 (es) 2021-10-20
US20170152297A1 (en) 2017-06-01
PH12016502012A1 (en) 2017-01-09
US20210371517A1 (en) 2021-12-02
RU2752275C2 (ru) 2021-07-26
US20210002364A1 (en) 2021-01-07
CN113528581A (zh) 2021-10-22
KR102618955B1 (ko) 2023-12-27
EP3943507A1 (en) 2022-01-26
US20170267742A1 (en) 2017-09-21
MY186846A (en) 2021-08-26
JP6772068B2 (ja) 2020-10-21
KR20160138298A (ko) 2016-12-02
JP7062720B2 (ja) 2022-05-06
US10266592B2 (en) 2019-04-23
EP4056201A1 (en) 2022-09-14
CN106661570A8 (zh) 2017-07-04
CN106535934A (zh) 2017-03-22
JP2021000117A (ja) 2021-01-07
KR102387243B1 (ko) 2022-04-14
IL248238A0 (en) 2016-11-30
JP2022153456A (ja) 2022-10-12
RU2016143384A3 (ru) 2018-11-30
AU2021200007A1 (en) 2021-03-04
MX395574B (es) 2025-03-25
MY185678A (en) 2021-05-30
JP6788573B2 (ja) 2020-11-25
ZA201607061B (en) 2024-05-30
CN106661570B (zh) 2020-02-07
BR112016023500A2 (pt) 2017-10-17
SG11201608395PA (en) 2016-11-29
IL248235A0 (en) 2016-11-30
WO2015157399A9 (en) 2016-11-24
EP3129053A1 (en) 2017-02-15
JP6788573B6 (ja) 2020-12-16
CA2945320A1 (en) 2015-10-15
CA2945303C (en) 2024-02-13
RU2016143388A (ru) 2018-05-14
KR102387243B9 (ko) 2023-07-10
IL297591B1 (en) 2025-01-01
MY192522A (en) 2022-08-25
NZ739448A (en) 2019-10-25
KR102508166B1 (ko) 2023-03-13
RU2016143388A3 (ru) 2018-11-30
AU2015243920A1 (en) 2016-11-03
US20220380461A1 (en) 2022-12-01
CN106574246A (zh) 2017-04-19
BR112016023517A2 (pt) 2017-10-17
CA2945303A1 (en) 2015-10-15
NZ725081A (en) 2018-02-23
KR102509481B1 (ko) 2023-03-10
SG11201608396YA (en) 2016-11-29
US12503507B2 (en) 2025-12-23
PH12016502009B1 (en) 2022-07-22
MX2016013160A (es) 2017-02-09
RU2751920C2 (ru) 2021-07-20
IL248238B1 (en) 2024-10-01
PH12016502011A1 (en) 2017-01-09
RU2729112C2 (ru) 2020-08-04
ES2880932T3 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
RU2016143384A (ru) Трансгенные генетические метки и способы применения
Palladini et al. Virus-like particle display of HER2 induces potent anti-cancer responses
JP2021036867A5 (ru)
JP2017518037A5 (ru)
US10106609B2 (en) CD7 nanobodies, encoding sequence and use thereof
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
RU2018118817A (ru) Химерные рецепторы антигена, нацеленные на her2
JP2019500894A5 (ru)
US20170342164A1 (en) ANTI-CD19 scFv (FMC63) POLYPEPTIDE
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
CN104177499B (zh) 一种嵌合抗原受体、编码基因、表达载体及其应用
HRP20211978T1 (hr) Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe
HRP20250397T1 (hr) Postupak i sastavi za staničnu imunoterapiju
JP2017537629A5 (ru)
JP2018529327A5 (ru)
JP2017537925A5 (ru)
JP2017500869A5 (ru)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2022501074A (ja) 血液腫瘍を治療するための遺伝子操作しているγδ−Ｔ細胞及び遺伝子操作していないγδ−Ｔ細胞に関する組成物及び方法
US20220185882A1 (en) Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
Singer et al. Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform
JP6755465B2 (ja) 共発現プラスミド
JP2022513321A (ja) 固形腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
WO2021092719A1 (zh) 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白